|
|
|
| Trends in incidence of notifiable infectious diseases in Nanjing City from 2004 to 2022 |
| ZHOU Qinyi, MA Tao, ZHAO Yueyuan, WANG Hengxue, WU Xiaoqing, DING Songning, SU Jingjing
|
| Nanjing Center for Disease Control and Prevention, Nanjing, Jiangsu 210009, China |
|
|
|
|
Abstract Objective To investigate the incidence trend and epidemic characteristics of notifiable infectious diseases in Nanjing City from 2004 to 2022, so as to provide the basis for improving the prevention, control, and monitoring strategies of infectious diseases. Methods Data pertaining to notifiable infectious diseases reported in Nanjing City from 2004 to 2022 were retrieved from the Infectious Disease Surveillance System of Chinese Disease Prevention and Control Information System. Infectious diseases were classified by law and transmission routes. Temporal distribution incidence of notifiable infectious diseases were descriptively analyzed. The trends in incidence of notifiable disease were analyzed using annual percent change (APC) and average annual percent change (AAPC). Results A total of 33 types of notifiable infectious diseases with 505 275 cases were reported in Nanjing City from 2004 to 2022. The average annual reported incidence was 347.45/105, showing a decreasing trend from 2018 to 2022 (APC=-13.499%, P<0.05), and there was no significant trend overall (AAPC=-1.586%, P>0.05). A total of 203 235 cases of 25 types of class A and B notifiable infectious diseases were reported, with an average annual reported incidence of 139.75/105, showing an overall decreasing trend (AAPC=-4.954%, P<0.05). Eight types of class C notifiable infectious diseases with 302 042 cases were reported, with an average annual reported incidence of 207.69/105. The reported incidence showed an increasing trend from 2004 to 2018 (APC=10.117%, P<0.05), and a decreasing trend from 2018 to 2022 (APC=-27.467%, P<0.05). There was no trend overall (AAPC=-0.360%, P>0.05). The reported incidence of blood-borne and sexually transmitted infectious diseases was the highest in class A and B infectious diseases, with an average annual reported incidence of 69.88/105, which was at a high epidemic level throughout the year, except February. The reported incidence of respiratory infectious diseases was 51.30/105, with a high reported incidence in April and December. The reported incidence of intestinal infectious diseases was the highest (178.06/105) in class C infectious diseases, with a high reported incidence in June and November. Conclusions The reported incidence of notifiable infectious diseases in Nanjing City was generally stable from 2004 to 2022. The peak incidence of respiratory infectious diseases occurred in winter and spring, and that of intestinal infectious diseases was in summer and autumn. It is necessary to strengthen the surveillance and intervention of blood-borne and sexually transmitted infectious diseases, respiratory infectious diseases, and intestinal infectious diseases to reduce the risk of infectious diseases.
|
|
Received: 10 January 2025
Revised: 24 April 2025
Published: 23 May 2025
|
|
|
|
|
|
[1] 杨维中. 我国传染病监测工作回顾与展望[J].中华预防医学杂志,2013,47(12):1075-1077.
YANG W Z.Review and prospect of infectious disease surveillance in China[J].Chin J Prev Med,2013,47(12):1075-1077.(in Chinese)
[2] 中华人民共和国国家卫生健康委员会.关于印发对新型冠状病毒感染实施“乙类乙管”总体方案的通知[EB/OL].[2025-04-24].http://www.nhc.gov.cn/xcs/zhengcwj/202212/e97e4c449d7a475794624b8ea12123c6.shtml.
[3] HU J L,LI W,PENG Z H,et al.Annual incidence and fatality rates of notifiable infectious diseases in southeast China from1950 to 2022 and relationship to socioeconomic development[J/OL].J Glob Health,2023[2025-04-24].https://pubmed.ncbi.nlm.nih.gov/37681663.DOI:10.7189/jogh.13.04107.
[4] 中华人民共和国国家卫生健康委员会.国家卫生计生委对关于调整部分法定传染病病种管理工作的解读[EB/OL].[2025-04-24].http://www.nhc.gov.cn/jkj/s3578/201311/7789c5099ea74630807bed6a2930aa6f.shtml.
[5] 王众楷,张白玉,贾善群,等.2008—2020年中国法定传染病的流行趋势分析[J].郑州大学学报(医学版),2022,57(3):350-356.
WANG Z K,ZHANG B Y,JIA S Q,et al.Analysis of epidemic trends of legal infectious diseases in China from 2008 to 2020[J].J Zhengzhou Univ(Med Sci),2022,57(3):350-356.(in Chinese)
[6] 赵跃媛,苏晶晶,周沁易,等.新型冠状病毒感染防控措施对南京市法定传染病流行特征的影响[J].医学动物防制,2024,40(10):946-949.
ZHAO Y Y,SU J J,ZHOU Q Y,et al.Influence of COVID-19 prevention and control measures on the epidemiological characteristics of notifiable infectious diseases in Nanjing City[J].J Med Pest Control,2024,40(10):946-949.(in Chinese)
[7] CURTIS N,FINN A,POLLARD A J.Hot topics in infection and immunity in children Ⅷ[M].New York:Springer,2012.
[8] 中华人民共和国国家卫生健康委员会.手足口病预防控制指南(2008年版)[EB/OL].[2025-04-24].http://www.nhc.gov.cn/wjw/gfxwj/201304/72a8f68053d742f392d8ff96bd9692fe.shtml.
[9] 任敏睿,崔金朝,聂陶然,等.2008—2018年中国手足口病重症病例流行病学特征分析[J].中华流行病学杂志,2020,41(11):1802-1807.
REN M R,CUI J C,NIE T R,et al.Epidemiological characteristics of severe cases of hand,foot,and mouth disease in China,2008-2018[J].Chin J Epidemiol,2020,41(11):1802-1807.(in Chinese)
[10] 中华人民共和国国家卫生健康委员会.关于印发流行性感冒诊疗方案(2020年版)的通知[EB/OL].[2025-04-24].http://www.nhc.gov.cn/yzygj/s7653p/202011/a943c67d55c74e589d23c81d
[11] 刘艳,沈建勇,王雨达,等. 2005—2023年湖州市法定传染病发病趋势分析[J]. 预防医学,2024,36(7):566-570.
LIU Y,SHEN J Y,WANG Y D,et al.Trends in incidence of notifiable infectious diseases in Huzhou City from 2005 to 2023[J].China Prev Med J,2024,36(7):566-570.(in Chinese)
[12] 中华人民共和国中央人民政府.公告2022年第7号[EB/OL].[2025-04-24].https://www.gov.cn/zhengce/zhengceku/2022-12/26/content_5733669.htm.
[13] 崔冉,李丽丽,田竞,等.2011—2020年北京市房山区其他感染性腹泻流行特征分析[J].河南预防医学杂志,2022,33(10):776-780.
CUI R,LI L L,TIAN J,et al.Epidemiological characteristics of other infectious diarrhea in Fangshan,Beijing from 2011 to 2020[J].Henan J Prev Med,2022,33(10):776-780.(in Chinese)
[14] 傅天颖,吴昊澄,鲁琴宝,等.2023年浙江省法定传染病疫情分析[J].预防医学,2024,36(5):369-373.
FU T Y,WU H C,LU Q B,et al.Analysis of notifiable infectious diseases in Zhejiang Province in 2023[J].China Prev Med J,2024,36(5):369-373.(in Chinese) |
| [1] |
DING Zheyuan, YANG Yan, FU Tianying, LU Qinbao, WANG Xinyi, WU Haocheng, LIU Kui, LIN Junfen, WU Chen. Analysis of notifiable infectious diseases in Zhejiang Province in 2024[J]. Preventive Medicine, 2025, 37(5): 433-438,442. |
|
|
|
|
